Market Research Report
Graft versus host disease (GVHD) - Epidemiology Forecast to 2030
|Graft versus host disease (GVHD) - Epidemiology Forecast to 2030|
DelveInsight Business Research LLP
Content info: 210 Pages
Delivery time: 2-10 business days
DelveInsight's 'Graft-versus-host disease (GvHD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host's tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem cell transplantation).The two main types of GvHD are acute GvHD and chronic GvHD.
Acute GvHD (aGvHD) might occur once the donor's cells have engrafted in the transplant recipient and have been observed to affect skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant. Acute GvHD is staged and graded (grade 0-IV) by the number and extent of organ involvement (skin, liver, and gastrointestinal). That staging is then used to determine the overall grade of the patient. Usually, patients with grade III-IV acute GvHD have a much worse outcome than those with grade I-II GvHD. The treatment depends on the grade of patient's GvHD. Chronic GvHD (cGvHD) usually develops later than 100 days after the transplant, and it might occur in the skin, liver, mouth, lungs, gastrointestinal tract, neuromuscular system, or genitourinary tract. Its diagnosis is based on manifestations and not timing. The doctor assesses the GvHD by looking at the number of organs involved and severity. Depending on this, they give it one of the following grades: mild, moderate and severe chronic GvHD. Patients who have an increased risk of developing chronic GvHD are: those who have received stem cells/bone marrow from an HLA mismatched related donor or from an HLA matched unrelated donor, use of peripheral blood stem cells (PBSCs), patients who may have already experienced acute GvHD, older transplant recipients and conditioning regimen.
The diagnosis of aGvHD is based wholly on clinical criteria that can be established by biopsy of one of the three target organs. Additionally, laboratory data and/or imaging studies are also useful tests in the diagnostic approach to GvHD. In cGvHD, some symptoms might be very ambiguous, which might make the diagnosis possible only after other causes are excluded. Some tests which are useful in diagnosis are biopsy (liver and skin), endoscopy, X-rays and scans, lung function tests and blood tests
Epidemiology Perspective by DelveInsight
The GvHD epidemiology division provides the insights about historical and current GvHD patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.The disease epidemiology covered in the report provides historical as well as forecasted GVHD epidemiology [segmented as Total Hematopoietic stem-cell transplantation (HSCT), Total Allogeneic Transplant cases, Total GvHD cases by Types (Acute and Chronic), Total Incident cases of aGvHD by Grading and organ Involvement, Total Incident cases of cGvHD by Grading and organ involvement, Total Treated patients of GvHD and Mortality adjusted GvHD treated patients] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
We interview, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over GVHD scenario of the indications.
Key Questions Answered
The GvHD Epidemiology report will allow the user to -
Study Period: 2018-2030
able 19 Mortality adjusted GvHD treated patients in the United States (2018-2030)